Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
September 08 2021 - 9:02AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16
OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2021
Commission
File Number: 001-36582
Altamira
Therapeutics Ltd.
(formerly
Auris Medical Holding Ltd.)
(Exact
name of registrant as specified in its charter)
Clarendon
House,
2 Church Street
Hamilton HM11, Bermuda
(Address of principal executive office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Yes ☐ No ☒
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Yes ☐ No ☒
INCORPORATION
BY REFERENCE
Exhibits
99.1 and 99.2 to this Report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form
F-3 (Registration Numbers 333-228121
and 333-249347) and
Form S-8 (Registration Numbers 333-232735
and 333-252141) of
Altamira Therapeutics Ltd. (formerly Auris Medical Holding Ltd.) and to be a part thereof from the date on which this report is
filed, to the extent not superseded by documents or reports subsequently filed or furnished.
Exhibit
99.3 to this Report on Form 6-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of
1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by
reference in any filing under the Securities Act of 1933 or the Exchange Act.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
Altamira
Therapeutics Ltd.
|
|
|
|
|
By:
|
/s/
Elmar Schaerli
|
|
|
Name:
|
Elmar
Schaerli
|
|
|
Title:
|
Chief
Financial Officer
|
Date:
September 8, 2021
EXHIBIT INDEX
3
false
--12-31
Q2
2021-06-30
0001601936
Altamira Therapeutics (NASDAQ:CYTO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Altamira Therapeutics (NASDAQ:CYTO)
Historical Stock Chart
From Sep 2023 to Sep 2024